| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | -0.039 | 0.4 |
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | 0.042 | 0.4 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | GW-2580 | GDSC1000 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.042 | 0.4 |
| mRNA | CBB-1007 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.4 |